Sanofi and GSK Next-Generation COVID-19 Vaccine Booster Shows Promise Against Omicron
Sanofi and GSK’s next-generation COVID-19 vaccine booster, which was developed to target the Beta variant of the SARS-CoV-2 virus, has demonstrated a significant antibody response against the Omicron variants in two clinical trials.
In one phase 3 study, participants who received the booster shot after being primed with a messenger RNA (mRNA) COVID-19 vaccine showed a 40-fold increase in antibodies against the Omicron BA.1 variant.
In a separate study, the new booster dose also demonstrated increased antibody responses against the Omicron BA.1 variant compared with Pfizer-BioNTech’s booster and Sanofi-GSK’s original booster, Sanofi said.
Global regulatory authorities are currently reviewing the original version of the booster, but the companies plan to submit the data supporting the next-generation booster within weeks, and are aiming to make the booster available later this year.